Learning objectives
To know the utility of 18F-FDG-PET and 18F-FDG-PET-CT in the different types of lymphomas,
in order to perform this test in those histological types of lymphoma in which the test has higher performance.
Background
18F-FDG-PET is approved by MEDICARE since July 2001 for the diagnosis,
staging and restaging of lymphoma,
and now these same applications are approved for hybrid PET-CT equipments.
We know there is a direct correlation between the degree of 18F-FDG and the histological grade of lymphomas.
This is because when the histological grade of tumor is higher,
this will behave more aggressively and will extend faster,
needing a major energy substrate,
which would explain the high affinity of these tumors by the 18F -FDG.
Findings and procedure details
The non-Hodgkin lymphomas (NHL) are divided into 3 groups according to the histological grade of malignancy:
LOW GRADE (40-45%): small cell follicular lymphoma,
lymphoplasmacytic lymphoma,
MALT lymphoma,
lymphocytic small cells lymphoma.
INTERMEDIATE LEVEL (40-45%) follicular large cell lymphoma,
diffuse lymphoma.
HIGH GRADE (5-10%): immunoblastic lymphoma,
lymphoblastic lymphoma,
Burkitt's lymphoma.
Hodgkin's disease is considered a high histological grade lymphoma.
Thus,
the 18F-FDG-PET has demonstrated a high sensitivity in Hodgkin lymphomas,
non-Hodgkin lymphoma,
in high grade non-Hodgkin lymphomas and in those which are low-grade that becomes high...
Conclusion
It is important to know the histological type of lymphoma before indicating the realization of a 18F-FDG-PET and 18F-FDG-PET-CT,
because there are types of lymphoma that would not benefit from this technique beeing more useful following them through conventional imaging techniques (ultrasound,
CT,
MRI).
References
- Fletcher,
James W.,
et al.
"Recommendations on the use of 18F-FDG PET in oncology."Journal of Nuclear Medicine49.3 (2008): 480-508.
-Moulin-Romsee,
Gerard,
et al.
"18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging."European journal of nuclear medicine and molecular imaging37.6 (2010): 1095-1105.
-Antoch,
Gerald,
et al.
"To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT."Journal of Nuclear Medicine45.1 suppl (2004): 56S-65S.
-Delbeke,
Dominique,
et al.
"Procedure guideline for...